Strona 4 - Najlepsi lekarze wykonujący biopsję płuc – TOP 111 lekarzy

Onkoginekolog

Onkolog

Ginekolog. Onkoginekolog

Onkolog, Kierownik Oddziału Urologii Samsung

Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

Dr Kemal Raşa jest bardzo doświadczonym chirurgiem ogólnym specjalizującym się w nowoczesnej tyreoidologii i chirurgii laparoskopowej z 23-letnim doświadczeniem. Jest członkiem kilku stowarzyszeń medycznych i opublikował kilka artykułów w swojej dziedzinie.

Dziedziny medycyny, które mnie interesują

• Chirurgia torakoskopowa i robotyczna małoinwazyjna

• Rak płuc

• Chirurgia tchawicy

• Transplantacja płuc

• Biopsja płuc • Odma opłucnowa (zapadnięte płuco)

• Chirurgia przepony • Chirurgia chorób opłucnej

• Chirurgia klatki piersiowej u dzieci

Edukacja

• Uniwersytet w Stambule, Wydział Lekarski w Stambule

•Szkoła średnia Galatasaray w Stambule

• Szkolnictwo podstawowe Ankara, Samsun, Izmir

Dr. Adnan Sayar is a leading thoracic surgeon in Turkey. He has over 40 years of medical experience and more than 30 years in thoracic surgery. He is known for his work in minimally invasive thoracoscopic and robotic procedures. These techniques have helped improve patient recovery and outcomes for chest diseases.

Dr. Sayar received international training at top centers, including Kyoto University and the Karolinska Institute. He is a key figure in lung transplantation and serves on Turkey’s Ministry of Health Lung Transplantation Scientific Committee. He also holds the FETCS certification from the European Board of Thoracic and Cardiovascular Surgery.

His expertise includes lung cancer surgery, tracheal and diaphragmatic reconstruction, and pediatric thoracic surgery. As a professor and mentor, he has led both public and private institutions. Dr. Sayar has helped thousands of patients and has played a major role in advancing thoracic care standards in Turkey.

Edukacja

Wydział Lekarski Uniwersytetu Cumhuriyet, 2004
Rezydentura z medycyny wewnętrznej w szpitalu badawczym Haydarpaşa w Stambule, 2010 r.
Karadeniz Technical University Wydział Lekarski Rezydentura z Onkologii Medycznej, 2015

Doświadczenie

Centrum Onkologiczne MD Andeson, USA, 2008
Klinika onkologiczna Sunnybrook Odette Cancer Center Breast Cancer Clinic, Kanada, 2017
Moffit Cancer Center, USA 2022
Szpital Kształcenia i Badań nad Medycyną Wewnętrzną w Stambule Haydarpaşa, 2010
Klinika chorób wewnętrznych Szpitala Państwowego w Idil, 2011
Karadeniz Technical University, Wydział Lekarski, Klinika Onkologii Medycznej, 2015
Szpital Kształcenia i Badań w Stambule Göztepe, Klinika Onkologii Medycznej, 2018
Szpital Uniwersytetu Yeniyüzyıl Gaziosmanpaşa, Klinika Onkologii Medycznej, 2020
Szpital Ataşehir Medicana, Klinika Onkologii Medycznej, 2022

Członkostwo naukowe

Tureckie Stowarzyszenie Medyczne (TTB)
Tureckie Towarzystwo Onkologii Medycznej (TTOD)
Europejskie Towarzystwo Onkologii Klinicznej (ESMO)
Amerykańskie Towarzystwo Onkologii Medycznej (ASCO)

Zainteresowania medyczne

• Rak piersi
• Rak płuc
• Rak jelita grubego
• Rak żołądka
• Rak odbytnicy
• Rak jajnika
• Rak wątroby
• Rak przełyku - Rak przełyku
• Rak nerki
• Rak krtani - Rak krtani
• Rak tarczycy
• Nowotwory głowy i szyi
• Nowotwory ginekologiczne
• Rak trzustki
• Rak przełyku - Rak przełyku
• Rak macicy
• Raki mózgu - Guzy mózgu
• Rak tkanek miękkich - mięsaki
• Rak prostaty
• Rak pęcherza moczowego
• Rak dróg żółciowych
• Rak jąder
• Rak szyjki macicy
• Rak jamy ustnej, języka i warg
• Nowotwory układu pokarmowego
• Guzy kości
• Rak tchawicy i oskrzeli
• Rak skóry - Rak skóry
• Guzy układu kostnego
• Rak pęcherzyka żółciowego
• Mezotelioma

Dr. Raj Nagarkar is a leading Surgical Oncologist with 19 years of experience. He has performed over 50,000 cancer surgeries. His main focus areas are Breast and Thoracic Surgical Oncology. He is involved in more than 200 clinical trials and has contributed to many national and international publications.

Dr. Nagarkar trained in Surgical Oncology at Tata Memorial Hospital, Mumbai. He also holds an MRCS from the Royal College of Surgeons, Edinburgh. He teaches DNB Superspecialty Surgical Oncology and Breast Surgery at Maharashtra University of Health Sciences. Dr. Nagarkar is dedicated to improving the quality of life for his patients.

Prof. ukończył Izmir Eşrefpaşa High School w 1996 r. Dr Serdar KALEMCİ ukończył Süleyman Demirel University Faculty of Medicine w 2003 r. W 2009 r. specjalizował się w Dokuz Eylül University Faculty of Medicine, Department of Chest Diseases. Ukończył obowiązkową służbę w Şanlıurfa Suruç State Hospital w 2010 r.

W 2015 roku otrzymał tytuł profesora nadzwyczajnego, pracując na Wydziale Lekarskim Uniwersytetu Muğla, w Katedrze Chorób Klatki Piersiowej. Kalemci prowadzi badania kliniczne i eksperymentalne w dziedzinie Chorób Klatki Piersiowej.

Ma 50 publikacji międzynarodowych. 4 z nich zostały opublikowane w SCI, a 36 w czasopismach SCI EXPANDED. Ma 20 publikacji krajowych. Wygłaszał ustne i pisemne prezentacje na wielu kongresach krajowych i międzynarodowych.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Edukacja

• Doktor medycyny: Wydział Lekarski Uniwersytetu Necmettin Erbakan Meram, 1994
• Rezydentura z medycyny wewnętrznej : Wydział Lekarski Uniwersytetu Atatürka, 2004
• Rezydentura z medycyny wewnętrznej : Wydział Lekarski Uniwersytetu Kafkasa, 2007
• Rezydentura w zakresie specjalizacji onkologii medycznej: Wydział Lekarski Uniwersytetu Selçuk, 2010
• Szkolenie w zakresie podspecjalizacji onkologii medycznej: Instytut Onkologii Uniwersytetu w Stambule, 2013

Doświadczenie

• Asystent dzienny: Wydział Lekarski Uniwersytetu Atatürka, 2005
• Asystent. Prof. Dr.: Uniwersytet Kafkasa, 2006-2007
• Adiunkt: Uniwersytet Selcuk - Onkologia medyczna, 2007-2010
• Asystent profesora: Instytut Onkologii Uniwersytetu w Stambule - Onkologia medyczna, 2012-2013
• Uzm. Dr.: Instytut Onkologii Uniwersytetu w Stambule - Onkologia medyczna, 2013-2017
• Prof. dr hab.: Instytut Onkologii Uniwersytetu w Stambule - Onkologia medyczna, 2017-2023
• Prof. Dr.: Instytut Onkologii Uniwersytetu w Stambule - Onkologia medyczna, 2023-obecnie

Członkostwa naukowe

• Tureckie Towarzystwo Onkologii Medycznej
• Europejskie Towarzystwo Onkologii Klinicznej (ESMO)
• Amerykańskie Towarzystwo Onkologii Klinicznej (ASCO)
• Tureckie Towarzystwo Specjalistyczne Medycyny Wewnętrznej

Nagrody

• 2018: Nagroda „Najlepszy badacz roku”, Instytut Onkologii Uniwersytetu w Stambule
• 2016: Nagroda motywacyjna TUBITAK w dziedzinie „Badania nad rakiem”

Dr. Kayihan Engin is a Radiation Oncologist. He earned his medical degree from Uludağ University Medical College in 1983. He completed his residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. From 1990 to 1994, he pursued a post-doctoral fellowship in Thermoradiotherapy at Thomas Jefferson University in the USA.

Dr. Engin has held key academic and leadership roles. He served as Professor, Chairman, and Faculty Accreditation Coordinator at Uludağ University Medical College from 1991 to 2005. He was also Professor and Director at Anadolu Medical Center between 2004 and 2017. Since 2017, he has led the Oncological Sciences departments at Ceylan International and Medicana Bursa Hospitals. Dr. Engin is known for his work in improving cancer treatment and medical education standards in Turkey.